GT Biopharma, Inc.
GTBP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 98.9% and free cash flow fell 41.3%, each against the same quarter a year earlier.
Follow GTBP
GT Biopharma, Inc. (GTBP) EV/Sales
As of 16 October 2026, GT Biopharma, Inc. (GTBP) trades at a EV/Sales of 543×. Over the past ten years it has ranged from −86.0× (December 2021) to 26,647,748× (April 2016); the current reading is higher than 85% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2015 | 1,774× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2015 | 1,774× | (34.68%) |
| Jun 2015 | 2,716× | (55.51%) |
| Mar 2015 | 6,105× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VAXX Vaxxinity, Inc. compare | −94.2× |
| AKTX Akari Therapeutics PLC compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | 0.1× |
| MRKR MARKER THERAPEUTICS, INC. compare | 1.9× |
| CNSY Cerenome, Inc. compare | 3.3× |
| DARE Dare Bioscience, Inc. compare | 4.7× |
| TVRD Tvardi Therapeutics, Inc. compare | 4.8× |
| GTBP GT Biopharma, Inc. | 543× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)